hackint0sh/New-Dataset huggingface dataset:
We will evaluate treatment outcomes of closed reduction and percutaneous cannulated screw fixation for tibial plateau fractures versus open reduction and fixation by plate conditions: Tibial Plateau Fractures Schatzker Type II studyType: INTERVENTIONAL phases: NA allocation: RANDOMIZED interventionModel: PARALLEL primaryPurpose: TREATMENT masking: NONE count: 10 type: ESTIMATED name: fixation of tibial plateau fractures measure: range of motion of knee joint using Rasmussen score sex: ALL minimumAge: 18 Years maximumAge: 70 Years stdAges: ADULT stdAges: OLDER_ADULT facility: Sohag university Hospital status: RECRUITING city: Sohag country: Egypt name: Magdy M Amin, professor role: CONTACT lat: 26.55695 lon: 31.69478 hasResults: False
nctId: NCT06353035 id: NaturalResourcesIFinland id: 346136 type: OTHER_GRANT domain: Strategic Research Council Finland id: 346138 type: OTHER_GRANT domain: Strategic Research Council Finland briefTitle: Biodiversity Interventions for Well-Being acronym: BIWE overallStatus: ACTIVE_NOT_RECRUITING date: 2022-03-30 date: 2027-06-30 date: 2027-09-30 date: 2024-04-08 date: 2024-04-08 name: Natural Resources Institute Finland class: OTHER_GOV name: Tampere University briefSummary: Biodiversity is essential for nature and human well-being. Land use has reduced biodiversity in cities, which weakens the functionality of the urban ecosystems and the well-being of citizens. This may also increase the risk of immune-mediated disorders among urban dwellers.
The investigators set up an intervention study in which urban private yards are rewilded with diverse vegetation and decaying deadwood and plant residuals. The investigators aim to evaluate the effect of rewilding, and yard management practices on commensal microbiome, cortisol levels and well-being and salivary cytokine levels, and gene pathways. conditions: Microbial Colonization conditions: Immune System Diseases conditions: Well-Being, Psychological conditions: Nature, Human studyType: INTERVENTIONAL phases: NA allocation: NON_RANDOMIZED interventionModel: PARALLEL interventionModelDescription: Intervention-control study in which intervention study subjects private yards are rewilded and control receives no treatment. primaryPurpose: BASIC_SCIENCE masking: NONE maskingDescription: The research subjects were not randomized or masked to the intervention and control group, because the control group needs volunteers who have no intention of following the yard management instructions advised to the intervention group. count: 30 type: ACTUAL name: Rewilding measure: Skin Gammaproteobacteria measure: Salivary cytokines measure: Difference in diversity (Alpha and beta diversity) of skin, saliva and stool microbiota measure: Difference in observed species richness of skin, saliva and stool microbiota measure: Difference in taxonomies of skin, saliva and stool microbiota measure: Difference in microbial gene pathways of saliva and stool microbiota measure: Cortisol levels measure: Perceived Stress Scale measure: Warwick-Edinburgh Mental Wellbeing Scale measure: Depression Scale measure: Nature Relatedness Scale measure: Metabolites in urine measure: Associations between environmental factors and microbial measurements, salivary cytokine levels, hair cortisol levels, perceived well-being sex: ALL minimumAge: 18 Years maximumAge: 72 Years stdAges: ADULT stdAges: OLDER_ADULT facility: Natural Resources Institute Finland city: Helsinki state: Uusimaa zip: 00970 country: Finland lat: 60.16952 lon: 24.93545 hasResults: False
nctId: NCT06353022 id: RC23_0267 id: 2023-508310-41 type: EUDRACT_NUMBER briefTitle: Minimal Residual Disease-based Strategy With T-Cell Redirector After Treatment With Daratumumab, Bortezomib, Lenalidomide, and Dexamethasone (D-VRd) in Newly Diagnosed Multiple Myeloma acronym: IFm2022-01 overallStatus: NOT_YET_RECRUITING date: 2024-04-20 date: 2026-04-20 date: 2030-06-20 date: 2024-04-08 date: 2024-04-08 name: Nantes University Hospital class: OTHER name: Janssen Pharmaceutica briefSummary: This is a Phase 2 study, open-label, 2-cohort, multicenter, national, interventional in patients with newly diagnosed multiple myeloma. The study will investigate teclistamab (Tec) in combination with lenalidomide (Len) (Tec-Len; Cohort A) or in combination with talquetamab (Tal) (Tec-Tal; Cohort B), allocated based on minimal residual disease (MRD) status (MRD \[-\] \[standard-risk\] vs MRD \[+\] \[high-risk\] respectively).
nctId: NCT06353009 id: ICM 2021-2720 briefTitle: Effect of a Single Ultra-Processed Meal on Myocardial Endothelial Function Assessed With Positron Emission Tomography acronym: SUPPER overallStatus: COMPLETED date: 2020-08-20 date: 2023-04-28 date: 2023-04-28 date: 2024-04-08 date: 2024-04-08 name: Matthieu Pelletier-Galarneau, MD MSc class: OTHER briefSummary: The objective of this study is to evaluate the effect of an ultra-processed meal on myocardial endothelial function using positron emission tomography (PET).
This project will contribute to clarify the role of diet in the development and progression of coronary artery disease. The results obtained from this study may potentially demonstrate the harmful effect of ultra-processed foods, even in the short term, on coronary arteries. conditions: Myocardial Endothelial Function studyType: INTERVENTIONAL phases: NA allocation: RANDOMIZED interventionModel: CROSSOVER primaryPurpose: BASIC_SCIENCE masking: SINGLE whoMasked: OUTCOMES_ASSESSOR count: 15 type: ACTUAL name: NOVA4 meal name: NOVA1-3 meal measure: Myocardial blood flow values (ml/min/g) at maximum dose of adenosine. measure: Myocardial blood flow values (ml/min/g) at rest and myocardial reserve. measure: Myocardial blood flow values (ml/min/g) at intermediate dose of adenosine. sex: MALE minimumAge: 18 Years maximumAge: 50 Years stdAges: ADULT facility: Matthieu Pelletier-Galarneau city: Montreal state: Quebec zip: H1T 1C8 country: Canada lat: 45.50884 lon: -73.58781 hasResults: False
nctId: NCT06352996 id: Dentist Anas Kassas briefTitle: Three-Dimensional Assessment of Maxillary Canine Retraction With and Without Power Arm overallStatus: ACTIVE_NOT_RECRUITING date: 2023-06-09 date: 2024-03-09 date: 2024-07-30 date: 2024-04-08 date: 2024-04-08 name: Mansoura University class: OTHER briefSummary: Aim of the study: This trial will be conducted for three-dimensional assessment of canine retraction with and without power arm.
Canine retraction using nickel titanium closed coil spring will start in the same day of upper first premolar extraction. conditions: Power Arm Canine Retraction studyType: INTERVENTIONAL phases: NA allocation: RANDOMIZED interventionModel: PARALLEL primaryPurpose: TREATMENT masking: SINGLE whoMasked: OUTCOMES_ASSESSOR count: 20 type: ESTIMATED name: Three-Dimensional Assessment of Maxillary Canine Retraction with Power Arm name: Three-Dimensional Assessment of Maxillary Canine Retraction without Power Arm measure: Canine tipping measure: Canine mobility measure: Implant stability measure: Pain assessment measure: canine rotation measure: canine retraction rate sex: ALL minimumAge: 14 Years maximumAge: 25 Years stdAges: CHILD stdAges: ADULT facility: Faculty of dentistry Mansoura University city: Mansoura country: Egypt lat: 31.03637 lon: 31.38069 hasResults: False
nctId: NCT06352983 id: 2014/11 briefTitle: Zirconium Dioxide Fixed Dental Prosthesis. overallStatus: COMPLETED date: 2017-12-20 date: 2019-09-27 date: 2023-01-20 date: 2024-04-08 date: 2024-04-08 name: Malmö University class: OTHER briefSummary: The purpose of this clinical trial is to evaluate and compare bridges to replace one or two missing teeth in the mouth. The bridges will be made of two variants of ceramic material. We will evaluate the bridges for up to five years regarding technical and biological complications. conditions: Missing Teeth studyType: INTERVENTIONAL phases: NA allocation: RANDOMIZED interventionModel: PARALLEL interventionModelDescription: Randomized controlled trial primaryPurpose: TREATMENT masking: QUADRUPLE maskingDescription: Both participant, care providers, dental technicians and the investigator are blinded in the process. whoMasked: PARTICIPANT whoMasked: CARE_PROVIDER whoMasked: INVESTIGATOR whoMasked: OUTCOMES_ASSESSOR count: 31 type: ACTUAL name: Fixed dental prosthesis measure: Fractures measure: De-bonding measure: Caries measure: Endodontic measure: Function measure: Esthetics sex: ALL stdAges: CHILD stdAges: ADULT stdAges: OLDER_ADULT facility: Malmo university city: Malmo state: Skane zip: 214 21 country: Sweden lat: 55.60587 lon: 13.00073 facility: Malmo university city: Malmo state: Skane zip: 21421 country: Sweden lat: 55.60587 lon: 13.00073 hasResults: False
nctId: NCT06352970 id: LundU-2024 briefTitle: Effects of Tuberculosis Infection on Development and Function of the Placenta overallStatus: NOT_YET_RECRUITING date: 2024-05-01 date: 2025-12-31 date: 2027-12-31 date: 2024-04-08 date: 2024-04-08 name: Lund University class: OTHER name: Addis Ababa University name: Armauer Hansen Research Institute, Ethiopia briefSummary: The goal of this observational study is to understand how tuberculosis (TB) infection impacts the function and development of the placenta, and whether TB infection can contribute to pregnancy-related disorders through effects on the placenta.
* Infant outcome at birth and at 6 weeks after birth conditions: Pregnancy Related conditions: Tuberculosis Infection conditions: Placenta Diseases studyType: OBSERVATIONAL observationalModel: COHORT timePerspective: PROSPECTIVE count: 500 type: ESTIMATED name: TB infection measure: Proportion of women with pathological placental findings according to the Amsterdam consensus criteria measure: Proportions of women with placental RNA and protein expression patterns linked to pregnancy- related disorders measure: Proportions of infants (born to participating women) with adverse outcome sex: FEMALE minimumAge: 18 Years stdAges: ADULT stdAges: OLDER_ADULT hasResults: False
nctId: NCT06352957 id: 23022022CERC briefTitle: Use of ETElcalcetidefor pReserving vitamiN K-dependent proteIn activiTY ITAlian Study acronym: ETERNITY-ITA overallStatus: NOT_YET_RECRUITING date: 2024-05-01 date: 2026-12-31 date: 2027-12-31 date: 2024-04-08 date: 2024-04-08 name: Istituto di Fisiologia Clinica CNR class: OTHER briefSummary: The goal of this Prospective Observational Study of comparative effectiveness is to provide real world evidence of the effect of Etelcalcetide in increasing actives form VKDPs levels such as BGP and MGP at 3, 9 and 18 months from baseline, with resulting correct bone mineralization and inhibition vascular calcification in hemodialysis patients.
The study will enroll 160 hemodialysis patients: 80 patients treated with Etelcalcetide and 80 age and sex matched patients treated with Calcitriol or vitamin D analogs. The treating nephrologist will base the target dose of Etelcalcetide on individual-level in order to achieve the KDIGO PTH target. In the Etelcalcetide-treated group, the addition of calcitriol will be allowed when required by clinical practice (for correction of hypocalcemia). The main endpoint is the comparison of the levels of active forms of VKDP (MGP and BGP) between patients treated with Etelcalcetide and those treated with vitamin D or vitamin D analogues. The measurements of the biomarkers are scheduled at baseline and after 3, 9, and 18 months. conditions: Hemodialysis studyType: OBSERVATIONAL observationalModel: COHORT timePerspective: PROSPECTIVE count: 160 type: ESTIMATED measure: Levels of VKDP measure: Calcium measure: Phosphate measure: Magnesium measure: ALP measure: PTH measure: 25(OH)D measure: P1NP measure: CTX measure: TRAP 5b measure: BSAP measure: cFGF23 measure: Klotho measure: Sclerostin measure: DKK1 measure: Fetuin A measure: Zinc measure: Irisin measure: Serum Calcification Propensity T50 test measure: Hemoglobin (Hb) measure: Hematocrit (Ht) measure: Plates (PLTS) measure: Reticulocytes measure: Iron measure: Ferritin measure: Transferrin measure: Transferrin Saturation measure: Albumin measure: KT/V measure: Aluminium measure: C-reactive Protein (CRP) measure: Cholesterol measure: Triglycerides measure: Cholesterol HDL measure: Cholesterol LDL measure: Vascular Calcification measure: Vertebral Fractures measure: BMD: Bone Mineral Density measure: Association between Verterbal Fractures and Vascular Calcificatiom measure: Novel quantitative computer-assisted scoring method for vascular calcifications. measure: Effect of Etelcalcetide on cardiovascular events and all-cause mortality. measure: Etelcalcetide Safety: Number of participants with treatment-related adverse events. sex: ALL minimumAge: 18 Years stdAges: ADULT stdAges: OLDER_ADULT hasResults: False
nctId: NCT06352944 id: AssiutMD briefTitle: Procalcitonin as a Marker of Severity of Non-cystic Fibrosis Bronchiectasis in Children overallStatus: NOT_YET_RECRUITING date: 2024-07 date: 2025-07 date: 2026-07 date: 2024-04-08 date: 2024-04-17 name: Assiut University class: OTHER briefSummary: The aim of this study is to evaluate the role of procalcitonin in bronchoalveolar lavage as a biomarker for assessment of severity of non-CF bronchiectasis in children in correlation with other markers (functional and radiological severity ) conditions: Non-cystic Fibrosis Bronchiectasis studyType: OBSERVATIONAL observationalModel: CASE_CONTROL timePerspective: CROSS_SECTIONAL count: 30 type: ESTIMATED name: procalcitonin measure: procalcitonin level in bronchoalveolar lavage as a biomarker for assessment of severity of non-CF bronchiectasis in children sex: ALL minimumAge: 6 Years maximumAge: 18 Years stdAges: CHILD stdAges: ADULT hasResults: False
nctId: NCT06352931 id: TCD & TCUS in infants briefTitle: Transcranial Ultrasound and Transcranial Doppler in Diagnosis and Detection of Outcome in Infants With Neurological Diseases overallStatus: NOT_YET_RECRUITING date: 2024-06-01 date: 2025-06-30 date: 2025-07-30 date: 2024-04-08 date: 2024-04-08 name: Assiut University class: OTHER briefSummary: To evaluate the accuracy of transcranial ultrasound in detection of brain pathology in infants with neurological diseases and value of transcranial Doppler in evaluation of intracerebral blood flow in comparison with other radiological modalities according to available imaging. conditions: Trancranial Doppler studyType: OBSERVATIONAL observationalModel: CASE_CROSSOVER timePerspective: CROSS_SECTIONAL count: 50 type: ESTIMATED name: transcranial and transcranial dopp;er measure: To evaluate the accuracy of transcranial ultrasound in detection of brain pathology in infants with neurological diseases and value of transcranial doppler sex: ALL minimumAge: 1 Day maximumAge: 1 Year stdAges: CHILD hasResults: False
nctId: NCT06352918 id: B.30.2.ATA.0.01.00/395 briefTitle: Peripheral Central Catheter (PICC) Care acronym: PICC overallStatus: COMPLETED date: 2023-05-01 date: 2023-11-30 date: 2023-12-31 date: 2024-04-08 date: 2024-04-08 name: Ataturk University class: OTHER briefSummary: Peripheral Central Catheter (PICC) is one of the painful interventions that are routinely performed repeatedly to establish a safe venous access in preterm babies.Nurses should reduce the pain of babies and ensure their comfort during interventions arising from the necessity of care processes.
Today, it is accepted that tactile stimuli, which have a pain-reducing effect on babies, should be used as a complementary treatment and care method. Palmar grasp reflex is one of the important tactile stimuli to reduce pain and provide comfort in babies. This research will be conducted to examine the effect of palmar grasp reflex stimulation on pain and comfort levels in PICC care in preterm babies. conditions: NEWBORN conditions: Pain, Acute studyType: INTERVENTIONAL phases: NA allocation: RANDOMIZED interventionModel: CROSSOVER primaryPurpose: SUPPORTIVE_CARE masking: TRIPLE whoMasked: PARTICIPANT whoMasked: INVESTIGATOR whoMasked: OUTCOMES_ASSESSOR count: 32 type: ACTUAL name: Palmar grasp reflex stimulation measure: Pain level measure: Comfort sex: ALL minimumAge: 28 Weeks maximumAge: 36 Weeks stdAges: CHILD facility: Ataturk University city: Erzurum zip: 25240 country: Turkey lat: 39.90861 lon: 41.27694 hasResults: False
nctId: NCT06352905 id: 2157711 briefTitle: Acute Effects of Whole Body Vibration for Individuals With Parkinson Disease overallStatus: RECRUITING date: 2022-09-01 date: 2025-04 date: 2025-04 date: 2024-04-08 date: 2024-04-08 name: Baylor University class: OTHER name: University of St. Augustine for Health Sciences briefSummary: This is an exploratory study to assess the impact of whole body vibration on backward walking speed in people with Parkinson disease. conditions: Parkinson Disease studyType: INTERVENTIONAL phases: NA allocation: NON_RANDOMIZED interventionModel: PARALLEL primaryPurpose: TREATMENT masking: NONE count: 40 type: ESTIMATED name: Whole body vibration (WBV) name: Control measure: 3-meter backward walk test (3MBWT) sex: ALL minimumAge: 40 Years maximumAge: 85 Years stdAges: ADULT stdAges: OLDER_ADULT facility: Baylor University status: RECRUITING city: Waco state: Texas zip: 76798 country: United States name: Anne Boddy role: CONTACT phone: 904-806-2126 email: anne_boddy@baylor.edu lat: 31.54933 lon: -97.14667 hasResults: False
nctId: NCT06352892 id: 20210201 briefTitle: A Study to Evaluate AMG 133 in Chinese Participants With Obesity or Overweight overallStatus: NOT_YET_RECRUITING date: 2024-04-24 date: 2024-09-03 date: 2024-09-03 date: 2024-04-08 date: 2024-04-08 name: Amgen class: INDUSTRY briefSummary: The main objective of the study is to assess the pharmacokinetics (PK) of AMG 133 after a single subcutaneous (SC) administration in overweight or obese Chinese participants. conditions: Obesity studyType: INTERVENTIONAL phases: PHASE1 allocation: RANDOMIZED interventionModel: PARALLEL primaryPurpose: TREATMENT masking: NONE count: 20 type: ESTIMATED name: AMG 133 measure: Maximum Observed Plasma Concentration (Cmax) of AMG 133 measure: Area Under the Plasma Concentration-time Curve (AUC) from Time Zero to the Last Quantifiable Concentration (AUClast) of AMG 133 measure: AUC from Time Zero Extrapolated to Infinity (AUCinf) of AMG 133 measure: Number of Participants with Treatment-emergent Adverse Events measure: Number of Participants with Serious Adverse Events measure: Number of Participants with Anti-AMG 133 Antibodies sex: ALL minimumAge: 18 Years maximumAge: 65 Years stdAges: ADULT stdAges: OLDER_ADULT hasResults: False
nctId: NCT06352879 id: 18-Al-KindyCM briefTitle: Prevalence, Types and Risk Factors of Urinary Incontinence Among Women in Baghdad, Iraq. overallStatus: RECRUITING date: 2024-03-01 date: 2024-05-31 date: 2024-06-15 date: 2024-04-08 date: 2024-04-08 name: Al-Kindy College of Medicine class: OTHER briefSummary: The goal of this observational study is to observe and describe the prevalence, types, and risk factors of urinary incontinence (UI) in adult women attending primary healthcare centers in Baghdad, Iraq. The main questions it aims to answer are:
* What is the effect of several risk factors on the occurrence and severity of urinary incontinence (including age, job, sexual activity, chronic constipation, chronic cough, parity, largest birth weight, and body mass index)? Participants will be asked to fill out a questionnaire consisting of the Arabic International Consultation On Incontinence Questionnaire-Urinary Incontinence Short Form (Arabic ICIQ-UI SF) in addition to questions about the aforementioned risk factors. conditions: Urinary Incontinence conditions: Urge Incontinence conditions: Stress Incontinence studyType: OBSERVATIONAL observationalModel: CASE_CONTROL timePerspective: CROSS_SECTIONAL count: 384 type: ESTIMATED measure: Arabic International Consultation On Incontinence Questionnaire-Urinary Incontinence Short Form (Arabic ICIQ-UI SF) measure: Risk factors for urinary incontinence sex: FEMALE minimumAge: 18 Years stdAges: ADULT stdAges: OLDER_ADULT facility: Baghdad Al- Karkh Health Directorate status: RECRUITING city: Baghdad country: Iraq name: Harth Mohamed Kamber, FICMS (Uro.) role: CONTACT phone: 009647706029071 email: harthkamber@kmc.uobaghdad.edu.iq name: Shahad Hameed Kadhom, MBChB role: PRINCIPAL_INVESTIGATOR lat: 33.34058 lon: 44.40088 facility: Baghdad Al-Russafa Health Directorate status: RECRUITING city: Baghdad country: Iraq name: Harth Mohamed Kamber, FICMS (Uro.) role: CONTACT phone: 009647706029071 email: harthkamber@kmc.uobaghdad.edu.iq name: Shahad Hameed Kadhom, MBChB role: PRINCIPAL_INVESTIGATOR lat: 33.34058 lon: 44.40088 hasResults: False
nctId: NCT06352866 id: CASE3A23 briefTitle: Siltuximab for Cytokine Release Syndrome Prophylaxis Prior to tx w/ Teclistamab in RRMM overallStatus: NOT_YET_RECRUITING date: 2024-07-01 date: 2025-04-01 date: 2025-12-01 date: 2024-04-08 date: 2024-04-16 name: Jack Khouri class: OTHER briefSummary: The purpose of this study is to examine the safety, efficacy and feasibility of the use of one standard dose of siltuximab prior to teclistamab infusion. Siltuximab is an investigational (experimental) drug that works by binding directly to human interleukin-6 (IL-6). IL-6 is a cytokine; these are products that are secreted by certain cells of the immune system and effect other cells in participant's body. IL-6 regulates immune, inflammatory and metabolic processes. Siltuximab has already been tested and approved for use by the FDA in participants with a condition called multicentric Castleman's disease, which is a lymphoproliferative disorder. This study is being conducted to investigate if administration of a single dose of siltuximab will reduce the rates of and severity of Cytokine Release Syndrome (CRS) and Immune effector Cell-Associated Neurotoxicity Syndrome (ICANS) in participants prior to teclistamab administration. CRS and ICANS are adverse effects commonly experienced by participants being treated with teclistamab that are related to inflammation in the body. Siltuximab is experimental because it is not approved by the Food and Drug Administration (FDA) for prophylactic use prior to administration of teclistamab infusion. conditions: Multiple Myeloma conditions: Cytokine Release Syndrome conditions: Refractory Multiple Myeloma conditions: Immune Effector Cell Associated Neurotoxicity Syndrome studyType: INTERVENTIONAL phases: PHASE2 allocation: NA interventionModel: SINGLE_GROUP interventionModelDescription: This study is an open label single cohort feasibility and efficacy study of siltuximab prophylaxis prior to infusion of teclistamab for treatment of RRMM. There is no planned dose escalation and no separate cohorts.
Participants will receive a single dose of prophylactic siltuximab, 11 mg/kg, 2 hours prior to the administration of the first dose of teclistamab on day 1. There is no planned dose escalation of siltuximab, and teclistamab dosing will be done following the standard planned ramp-up. Participants will be hospitalized for 9 days according to teclistamab package insert and Cleveland Clinic institutional practice. Participants will be followed for the incidence of CRS and ICANS for the first two 22-day cycles of treatment. primaryPurpose: SUPPORTIVE_CARE masking: NONE count: 20 type: ESTIMATED name: Siltuximab name: Teclistamab(FDA-approved) measure: Change in CRS Rate measure: Safety assessment of a single dose of siltuximab as CRS prophylaxis measure: Incidence of grade ≥ 2 cytokine release syndrome after siltuximab prophylaxis measure: Incidence of all grade ICANS after siltuximab prophylaxis measure: Incidence of adverse events after siltuximab prophylaxis measure: Overall response rate measure: Progression free survival measure: Overall survival measure: Hospitalization rates sex: ALL minimumAge: 18 Years stdAges: ADULT stdAges: OLDER_ADULT facility: Cleveland Clinic Taussig Cancer Center, Case Comprehensive Cancer Center Cleveland, Ohio city: Cleveland state: Ohio zip: 44195 country: United States name: Jack Khouri, MD role: CONTACT phone: 866-223-8100 email: TaussigResearch@ccf.org name: Jack Khouri, MD role: PRINCIPAL_INVESTIGATOR lat: 41.4995 lon: -81.69541 hasResults: False